Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.04
MYL's Cash to Debt is ranked lower than
61% of the 750 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.39 vs. MYL: 0.04 )
MYL' s 10-Year Cash to Debt Range
Min: 0.04   Max: 38.64
Current: 0.04

0.04
38.64
Equity to Asset 0.19
MYL's Equity to Asset is ranked lower than
57% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.60 vs. MYL: 0.19 )
MYL' s 10-Year Equity to Asset Range
Min: 0.19   Max: 0.9
Current: 0.19

0.19
0.9
Interest Coverage 3.62
MYL's Interest Coverage is ranked lower than
53% of the 462 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 90.51 vs. MYL: 3.62 )
MYL' s 10-Year Interest Coverage Range
Min: 0.83   Max: 9.19
Current: 3.62

0.83
9.19
F-Score: 5
Z-Score: 1.74
M-Score: -2.44
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 16.44
MYL's Operating margin (%) is ranked higher than
86% of the 713 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.34 vs. MYL: 16.44 )
MYL' s 10-Year Operating margin (%) Range
Min: 2.31   Max: 36
Current: 16.44

2.31
36
Net-margin (%) 9.03
MYL's Net-margin (%) is ranked higher than
77% of the 713 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.50 vs. MYL: 9.03 )
MYL' s 10-Year Net-margin (%) Range
Min: -3.53   Max: 30.52
Current: 9.03

-3.53
30.52
ROE (%) 21.20
MYL's ROE (%) is ranked higher than
96% of the 716 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. MYL: 21.20 )
MYL' s 10-Year ROE (%) Range
Min: -6.7   Max: 25.05
Current: 21.2

-6.7
25.05
ROA (%) 4.09
MYL's ROA (%) is ranked higher than
72% of the 745 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.95 vs. MYL: 4.09 )
MYL' s 10-Year ROA (%) Range
Min: -1.74   Max: 22.13
Current: 4.09

-1.74
22.13
ROC (Joel Greenblatt) (%) 34.10
MYL's ROC (Joel Greenblatt) (%) is ranked higher than
90% of the 735 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.63 vs. MYL: 34.10 )
MYL' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 4.09   Max: 90.88
Current: 34.1

4.09
90.88
Revenue Growth (%) 1.90
MYL's Revenue Growth (%) is ranked higher than
63% of the 549 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. MYL: 1.90 )
MYL' s 10-Year Revenue Growth (%) Range
Min: -6.1   Max: 54.5
Current: 1.9

-6.1
54.5
EBITDA Growth (%) 5.90
MYL's EBITDA Growth (%) is ranked higher than
72% of the 504 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.00 vs. MYL: 5.90 )
MYL' s 10-Year EBITDA Growth (%) Range
Min: -20   Max: 107
Current: 5.9

-20
107
EPS Growth (%) 32.40
MYL's EPS Growth (%) is ranked higher than
89% of the 506 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.70 vs. MYL: 32.40 )
MYL' s 10-Year EPS Growth (%) Range
Min: -28.8   Max: 110.4
Current: 32.4

-28.8
110.4
» MYL's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

MYL Guru Trades in Q1 2013

Vanguard Health Care Fund 4,176,100 sh (New)
Paul Tudor Jones 32,400 sh (New)
Ray Dalio 292,989 sh (+609.61%)
Jim Simons 2,487,100 sh (+383.59%)
Tom Russo 3,500 sh (unchged)
Mario Gabelli 20,085 sh (unchged)
Louis Moore Bacon Sold Out
Ken Heebner Sold Out
Scott Black 370,954 sh (-2.65%)
John Paulson 18,073,400 sh (-26.24%)
Joel Greenblatt 16,825 sh (-76.1%)
Steven Cohen 311,554 sh (-88.65%)
» More
Q2 2013

MYL Guru Trades in Q2 2013

John Hussman 800,000 sh (New)
Paul Tudor Jones 465,100 sh (+1335.49%)
Joel Greenblatt 129,295 sh (+668.47%)
Steven Cohen 1,053,705 sh (+238.21%)
Vanguard Health Care Fund 4,775,700 sh (+14.36%)
Scott Black 378,284 sh (+1.98%)
Louis Moore Bacon 600,000 sh (unchged)
Tom Russo Sold Out
Stanley Druckenmiller Sold Out
John Paulson 12,139,300 sh (-32.83%)
Mario Gabelli 13,000 sh (-35.28%)
Ray Dalio 61,097 sh (-79.15%)
Jim Simons 503,200 sh (-79.77%)
» More
Q3 2013

MYL Guru Trades in Q3 2013

Caxton Associates 200,000 sh (New)
Mario Gabelli 13,000 sh (unchged)
Vanguard Health Care Fund 4,775,700 sh (unchged)
John Paulson 12,139,300 sh (unchged)
Ray Dalio Sold Out
Jim Simons Sold Out
Scott Black 359,799 sh (-4.89%)
Paul Tudor Jones 431,700 sh (-7.18%)
John Hussman 454,000 sh (-43.25%)
Steven Cohen 524,317 sh (-50.24%)
Joel Greenblatt 10,695 sh (-91.73%)
» More
Q4 2013

MYL Guru Trades in Q4 2013

David Dreman 1,221 sh (New)
Vanguard Health Care Fund 4,775,700 sh (unchged)
Mario Gabelli 13,000 sh (unchged)
John Paulson 12,139,300 sh (unchged)
Paul Tudor Jones Sold Out
Caxton Associates Sold Out
Steven Cohen 519,430 sh (-0.93%)
Scott Black 307,214 sh (-14.62%)
Joel Greenblatt 7,291 sh (-31.83%)
John Hussman 200,000 sh (-55.95%)
» More
» Details

Insider Trades

Latest Guru Trades with MYL

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Hussman 2013-12-31 Reduce -55.95%0.53%$37.865 - $44.5 $ 46.9214%200000
Scott Black 2013-12-31 Reduce -14.62%0.23%$37.865 - $44.5 $ 46.9214%307214
Joel Greenblatt 2013-12-31 Reduce -31.83%$37.865 - $44.5 $ 46.9214%7291
David Dreman 2013-12-31 New Buy$37.865 - $44.5 $ 46.9214%1221
John Hussman 2013-09-30 Reduce -43.25%0.48%$30.37 - $38.95 $ 46.9233%454000
Joel Greenblatt 2013-09-30 Reduce -91.73%0.16%$30.37 - $38.95 $ 46.9233%10695
Ray Dalio 2013-09-30 Sold Out 0.02%$30.37 - $38.95 $ 46.9233%0
John Hussman 2013-06-30 New Buy1.1%$27.96 - $31.87 $ 46.9257%800000
John Paulson 2013-06-30 Reduce -32.83%0.98%$27.96 - $31.87 $ 46.9257%12139300
Joel Greenblatt 2013-06-30 Add 668.47%0.15%$27.96 - $31.87 $ 46.9257%129295
Ray Dalio 2013-06-30 Reduce -79.15%0.06%$27.96 - $31.87 $ 46.9257%61097
Mario Gabelli 2013-06-30 Reduce -35.28%$27.96 - $31.87 $ 46.9257%13000
John Paulson 2013-03-31 Reduce -26.24%1.08%$27.45 - $31.01 $ 46.9262%18073400
Vanguard Health Care Fund 2013-03-31 New Buy0.48%$27.45 - $31.01 $ 46.9262%4176100
Joel Greenblatt 2013-03-31 Reduce -76.1%0.08%$27.45 - $31.01 $ 46.9262%16825
Ray Dalio 2013-03-31 Add 609.61%0.07%$27.45 - $31.01 $ 46.9262%292989
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Mylan Inc

S&P Winners Broadly Held by Billionaires
Over 12 months, FLIR Systems Inc. (FLIR) is up 61%, Mylan Inc. (MYL) is up 64% and Nabors Industries Ltd. (NBR) is up 24%, making them three of the biggest winners in the S&P 500. Here’s a company update about the top billionaire stakeholders, as of June 30, 2013. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 29.50
MYL's P/E(ttm) is ranked higher than
65% of the 527 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.60 vs. MYL: 29.50 )
MYL' s 10-Year P/E(ttm) Range
Min: 6.13   Max: 112.56
Current: 29.5

6.13
112.56
P/B 5.90
MYL's P/B is ranked lower than
60% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.84 vs. MYL: 5.90 )
MYL' s 10-Year P/B Range
Min: 0.64   Max: 6.93
Current: 5.9

0.64
6.93
P/S 2.68
MYL's P/S is ranked higher than
59% of the 717 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.95 vs. MYL: 2.68 )
MYL' s 10-Year P/S Range
Min: 0.56   Max: 5.69
Current: 2.68

0.56
5.69
PFCF 24.00
MYL's PFCF is ranked higher than
69% of the 328 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 24.79 vs. MYL: 24.00 )
MYL' s 10-Year PFCF Range
Min: 7.74   Max: 82
Current: 24

7.74
82
EV-to-EBIT 22.20
MYL's EV-to-EBIT is ranked higher than
60% of the 593 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.45 vs. MYL: 22.20 )
MYL' s 10-Year EV-to-EBIT Range
Min: 6.4   Max: 40
Current: 22.2

6.4
40
PEG 4.20
MYL's PEG is ranked higher than
56% of the 309 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.80 vs. MYL: 4.20 )
MYL' s 10-Year PEG Range
Min: 0.37   Max: 11.64
Current: 4.2

0.37
11.64
Shiller P/E 67.00
MYL's Shiller P/E is ranked lower than
59% of the 363 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.59 vs. MYL: 67.00 )
MYL' s 10-Year Shiller P/E Range
Min: 9.55   Max: 701
Current: 67

9.55
701

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 2.50
MYL's Price/DCF (Projected) is ranked higher than
57% of the 349 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.70 vs. MYL: 2.50 )
MYL' s 10-Year Price/DCF (Projected) Range
Min: 0.76   Max: 2.28
Current: 2.5

0.76
2.28
Price/Median PS Value 1.40
MYL's Price/Median PS Value is ranked lower than
51% of the 675 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.10 vs. MYL: 1.40 )
MYL' s 10-Year Price/Median PS Value Range
Min: 0.34   Max: 3.3
Current: 1.4

0.34
3.3
Price/Peter Lynch Fair Value 3.80
MYL's Price/Peter Lynch Fair Value is ranked lower than
66% of the 149 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.40 vs. MYL: 3.80 )
MYL' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.75   Max: 4.52
Current: 3.8

0.75
4.52
Earnings Yield (Greenblatt) 4.50
MYL's Earnings Yield (Greenblatt) is ranked higher than
66% of the 595 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.80 vs. MYL: 4.50 )
MYL' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2.5   Max: 15.6
Current: 4.5

2.5
15.6
Forward Rate of Return (Yacktman) 9.85
MYL's Forward Rate of Return (Yacktman) is ranked higher than
82% of the 531 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.45 vs. MYL: 9.85 )
MYL' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 5.3   Max: 38.9
Current: 9.85

5.3
38.9

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:MYL.Germany
Mylan, Inc. was incorporated in Pennsylvania in 1970. The Company and its subsidiaries comprise a global pharmaceutical company that develops, licenses, manufactures, markets and distributes generic and branded generic pharmaceuticals, specialty pharmaceuticals and active pharmaceutical ingredients. The Company has two reportable segments, the Generics Segment and the Specialty Segment. The principal markets for the Generics Segment products are proprietary and ethical pharmaceutical wholesalers and distributors, drug store chains, drug manufacturers, institutions, and public and governmental agencies primarily within the United States and Canada, Europe, the Middle East and Africa, Australia, Japan, India and New Zealand. The Generics Segment also develops active pharmaceutical ingredients with non-infringing processes to partner with generic manufacturers in regulated markets such as the U.S. and European Union at market formation. The principal market for the Specialty Segment products is pharmaceutical wholesalers and distributors, pharmacies and health care institutions primarily in the U.S. The specialty business is engaged respiratory, allergy and psychiatric therapies. The Company's active pharmaceutical ingredient business is conducted through Mylan Laboratories Limited. It also manufactures and supplies low cost, high quality active pharmaceutical ingredients for its own products and pipeline, as well as for third parties. During 2012, it completed more than 690 global country level product submissions, which included 88 in North America, 375 in EMEA and 229 in Asia Pacific. The Company's EPIPEN Auto-Injector is the number one prescribed epinephrine auto-injector. It markets a global portfolio of approximately 1,100 different products covering a vast array of therapeutic categories. In the U.S., the company has products portfolio consisting of approximately 365 products, of which approximately 310 are in capsule or tablet form in an aggregate of approximately 880 dosage strengths. Included in these totals are approximately 40 extended-release products in a total of approximately 105 dosage strengths.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide